EL7.AI
StocksMedium•16 November 2026•
5 min read

Novo Nordisk presents semaglutide trial results in 165 children with obesity

Key Facts

1The STEP Young trial included 165 children aged 6 to under 12.
2At week 68, 40.4% of the semaglutide group were no longer classified as having obesity, compared with none in the placebo group.
3The primary endpoint was the change in body mass index through week 68; the company said the reduction was greater with semaglutide.
4More than 85% of participants had class II or III severe obesity at the start of the trial.

On November 16, Novo Nordisk presented results from the STEP Young trial, which tested semaglutide in 165 children with obesity, aged 6 to under 12. The company included the results in the ObesityWeek program during a session scheduled from 10:00 to 11:30 a.m. Eastern time. The Phase 3 trial compared semaglutide with placebo in a randomized, double-blind, multinational study. The company said the trial met its primary endpoint, the change in body mass index from baseline to week 68. The results represent clinical data for this age group, while their presentation alone does not establish that the company has received regulatory approval to use the treatment in this population.

Body mass index at week 68 was the prespecified primary measure for comparing the groups, and Novo Nordisk said the reduction in this measure was greater among children who received semaglutide than among those who received placebo. The information available here did not include the numerical change in the measure, so the company’s announcement about the primary endpoint describes the direction of the comparison, not the size of the reduction. This measure differs from the share of children who were no longer classified as having obesity, another outcome reported by the company for the same period. The distinction between the measures defines what each result captures: a change in the average measure from baseline versus some participants moving to a different classification. In both analyses, the comparison was between the treatment and placebo groups in the same trial.

The company said 40.4% of children in the semaglutide group were no longer classified as having obesity at week 68, compared with no children in the placebo group. The figure does not mean those children lost 40.4% of their body weight; it measures the proportion no longer classified as having obesity, according to the company’s definition of the outcome. The analysis was based on the assumption that all children adhered to treatment throughout the evaluation period, using an estimate of the treatment effect if participants adhered. The result is therefore tied to a specific analytical assumption as well as the measurement at week 68. The comparison with the placebo group puts the classification outcome in the context of the trial without turning it into a measure of weight loss.

The trial began with participants who had high levels of obesity: Novo Nordisk said more than 85% of the children had class II or III severe obesity at baseline. The children received maximum weekly semaglutide doses of 1.7 or 2.4 mg, depending on their weight at the start of the trial. Participants in both the treatment and placebo groups also received lifestyle interventions, making lifestyle intervention part of the study’s accompanying program. This design means the comparison was not between receiving the drug and receiving no intervention, but between two groups whose members received lifestyle interventions alongside different drug treatments. The allocation between the two doses was linked to the child’s weight at the start of the trial, according to the company’s statement.

On safety, the company said the safety and tolerability results were consistent with previous trials and that it had identified no new safety signals related to growth or pubertal development. This means the company reported no new concerns in these two areas in the results it announced, with the description remaining attributable to its statement. Growth and puberty are particularly relevant in a study involving children under 12, as both were explicitly monitored in the safety summary. The information provided did not include numerical details on adverse events or withdrawal rates, so the safety summary is limited to the company’s statement that the results were consistent with previous trials and no new signals were observed. Novo Nordisk’s chief scientific officer said the company was "optimistic about the positive results of the STEP Young trial and the potential of semaglutide to help children with obesity who need medical treatment alongside lifestyle changes."

The U.S. Food and Drug Administration’s current label allows Wegovy injections to be used for weight reduction in adults and children with obesity aged 12 and older, and states that safety and effectiveness for this use have not been established in those under 12. The age group studied in STEP Young therefore falls below the age threshold specified in the label, making the results potentially relevant to treatment and regulation without in themselves representing an approved expansion of use. In the United States, Reuters reported that prescriptions of GLP-1 drugs for weight loss in children under 12 have risen more than 300-fold since 2019, despite the drugs not being approved for that age group. This increase places prescriptions for children in the context of interest in using these drugs, while the age approved on the Wegovy label remains 12 and older. It has not been verified whether Novo Nordisk has submitted a new regulatory application or the timeline for any such step.

Open on chart